{"filings":[{"id":610878,"accession_number":"0001683168-26-004268","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2026-05-22T20:43:53+00:00","items":["5.07"],"status":"ready","headline":"Actuate Therapeutics holds 2026 Annual Meeting; elects Fletcher and Keyes as directors, ratifies Crowe LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Aaron G.L. Fletcher, Ph.D. and Jason Keyes as Class II directors for three-year terms through 2029.","Fletcher received 14,877,247 for, 1,883,025 withheld; Keyes received 16,727,875 for, 32,397 withheld.","Ratified Crowe LLP as independent auditor for FY 2026 with 18,571,817 for, 50,023 against, 9,741 abstain.","Broker non-votes: 1,871,309 on director elections; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15605,"accession_number":"0001683168-26-003684","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2026-05-11T21:27:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Actuate Therapeutics receives FDA IND clearance for oral elraglusib Phase 1/2 study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for Phase 1/2 study of oral elraglusib tablet in advanced solid tumors; initiation planned for 2H 2026.","Oral formulation aims to achieve higher exposure than IV; PK exposure correlated with improved OS in mPDAC Phase 2.","Elraglusib plus RAS inhibitor preclinical results expected mid-2026; combination potential in RAS-driven cancers.","Industry veteran Martin Huber, MD, appointed to Board; former President and CEO of Mersana Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94432,"accession_number":"0001683168-26-003515","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Actuate Therapeutics appoints former Mersana CEO Martin Huber to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8; Huber appointed as Class III director effective May 1, 2026.","Huber previously President/CEO of Mersana until Jan 2026 acquisition by Day One Biopharmaceuticals.","Receives initial option grant of 30,000 shares (3-year vest), annual retainer $44,000, plus $3,000/quarter consulting fee.","He will serve on Nominating and Corporate Governance Committee; expertise includes approvals of pembrolizumab, niraparib, others.","Company highlights his role in advancing elraglusib for difficult-to-treat cancers including metastatic pancreatic cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106812,"accession_number":"0001683168-26-000217","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Actuate Phase 2 pancreatic cancer trial meets OS endpoint; elraglusib+GnP reduces death risk 38%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 10.1 mo (elraglusib/GnP) vs 7.2 mo (GnP alone); HR=0.62, p=0.02.","12-month survival doubled: 44.4% vs 22.3%; 24-month survival fivefold: 12.9% vs 2.6%.","Safety profile consistent; serious TEAE 56.1% vs 56.4%; death-related TEAE 12.3% vs 16.7%.","Biomarker data suggest potential predictive value for KRAS, ARID1A; increased CD8+ and NK cells in combination arm.","Seventeen patients remain alive in elraglusib arm (3 >24 mo); none on GnP alone as of Nov 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123116,"accession_number":"0001683168-25-008732","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Actuate Therapeutics enters $100M ATM equity offering agreement with B. Riley and Craig-Hallum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows sale of up to $100M of common stock through agents B. Riley Securities and Craig-Hallum Capital Group.","Sales will be made under existing S-3 shelf registration; agents receive 3.0% commission on gross proceeds.","Offers may be executed as at-the-market, privately negotiated, or block transactions at company's discretion.","Company provides customary indemnification to the sales agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123115,"accession_number":"0001683168-25-008618","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Actuate Therapeutics lists official disclosure channels including social media","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company announced it will use website, press releases, SEC filings, and social media for material information.","Social media channels include X (@ActuateThera), LinkedIn, and Facebook.","Investors can subscribe to press releases and SEC filings on the company's investor relations page.","List may be updated from time to time; no other material news disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139801,"accession_number":"0001683168-25-006831","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Actuate Therapeutics prices $15M public offering of 2.14M shares at $7.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offers 2,142,858 shares at $7.00/share; gross proceeds ~$15M before discounts and expenses.","Underwriters granted 30-day over-allotment option for up to 321,428 additional shares.","Closing expected September 11, 2025; proceeds for working capital and general corporate purposes.","Directors and executive officers subject to lock-up until December 9, 2025.","Lucid Capital Markets sole book-runner; Titan Partners Group as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157391,"accession_number":"0001683168-25-004766","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Actuate Therapeutics raises ~$4.7M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approx. $4.7M from sale of 666,497 shares at $7.00/share and warrants to purchase 666,497 shares.","Warrants exercisable at $7.00 for 20 days after Milestone Date (FDA Breakthrough Therapy or registration determination for elraglusib).","Bios 2024 Co-Invest, LP (affiliated with Chairman Dr. Aaron G.L. Fletcher) purchasing 71,428 shares and warrants for ~$500K.","Closing expected on or before June 30, 2025; proceeds for working capital and general corporate purposes.","Registration rights agreement requires filing resale registration statement by August 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157390,"accession_number":"0001683168-25-004258","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Actuate Therapeutics presents Phase 2 elraglusib data showing overall survival benefit in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 (Actuate-1801 Part 3B) data of elraglusib with gemcitabine/nab-paclitaxel showed overall survival benefit in first-line metastatic pancreatic cancer.","KOL event featured four GI oncology experts who discussed elraglusib's mechanism targeting EMT, NF-kB, and immune activation.","Dr. Colin Weekes stated elraglusib is the first drug in years to improve outcomes on standard chemotherapy backbones.","Drug was well-tolerated; neutropenia occurred but no febrile neutropenia; transient vision changes resolved within 24 hours.","Study PI Dr. Deva Mahalingam highlighted unique GSK-3 beta inhibition and survival curve separation in a challenging patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157389,"accession_number":"0001683168-25-004117","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Actuate reports Phase 2 elraglusib/GnP meets primary OS endpoint in mPDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["mOS 10.1 months vs 7.2 months for GnP alone, HR=0.63, log-rank p=0.01, 37% risk reduction.","12-month OS rate 44.1% vs 22.3% (p=0.0005); 24-month OS rate 13.8% vs 0%.","ORR 29.0% vs 21.8%; DCR 61.3% vs 56.4%; mPFS 5.6 vs 5.1 months (HR=0.90, not significant).","Safety profile similar between arms; transient, reversible visual impairments most common TRAEs.","Company plans to request pre-NDA meeting with FDA in 2H 2025 for registration path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157388,"accession_number":"0001683168-25-003995","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Actuate Therapeutics shareholders elect three Class I directors, ratify Crowe as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Roger Sawhney re-elected with 14,216,991 votes for, 1,200 withheld.","Mr. Todd Thomson re-elected with 14,058,447 for, 159,744 withheld.","Dr. Dan Zabrowski re-elected with 14,009,434 for, 208,757 withheld.","Ratification of Crowe LLP as independent auditor passed with 15,098,549 for, 150,679 against.","Broker non-votes of 1,045,368 on director elections and none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157387,"accession_number":"0001683168-25-003163","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Actuate elraglusib Phase 2 meets primary endpoint with statistically significant OS improvement in mPDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elraglusib plus GnP showed statistically significant overall survival improvement vs GnP alone in first-line mPDAC.","Median overall survival substantially improved from December 2024 analysis; 1-year survival rate also significantly increased.","Trial achieved primary endpoint; favorable risk-benefit profile; data to be presented at ASCO on May 31, 2025.","Company plans to meet with US and EU regulators in H2 2025 to advance toward NDA and registration.","This is the first major advance in first-line mPDAC survival in over a decade, per management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175752,"accession_number":"0001683168-25-001945","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Actuate Therapeutics enters $50M equity line with B. Riley, can sell shares at 3% VWAP discount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $50M of common stock to B. Riley Principal Capital II over 36 months at a 3% discount to VWAP.","Sales are at Actuate's sole discretion; no obligation to sell any shares under the agreement.","Beneficial ownership by B. Riley capped at 4.99%; exchange cap of 19.99% of shares outstanding unless higher threshold price met.","Actuate paid a cash commitment fee of up to $500,000 (1% of facility) and will reimburse legal fees.","Proceeds intended for working capital and general corporate purposes; company retains right to terminate at any time with 10 trading days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175751,"accession_number":"0001683168-25-000826","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Actuate Therapeutics sets first annual meeting for May 22, 2025; deadlines announced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Annual Meeting of Stockholders will be held virtually on May 22, 2025.","Record date for voting entitlement is March 25, 2025.","Rule 14a-8 stockholder proposals must be received by February 21, 2025, for proxy inclusion.","Advance notice for director nominations and other proposals also due by February 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192690,"accession_number":"0001683168-24-008794","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Actuate Therapeutics: elraglusib Phase 2 meets primary endpoint; 1-year survival 43.6% vs 22.5% in mPDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-year survival rate 43.6% in elraglusib+GnP arm vs 22.5% in GnP alone (p=0.002); median OS 9.3 vs 7.2 months (HR=0.63, p=0.016).","37% reduction in risk of death; ORR 27.7% vs 20.5%; multiple patients with complete/partial responses and 100% target lesion reduction.","Favorable safety profile; TEAEs and SAEs similar between arms; 2 patients with previously inoperable lesions successful resected.","Trial fully enrolled (286 patients); topline data expected 1H 2025; planned FDA engagement for Phase 3 registration trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192689,"accession_number":"0001683168-24-007857","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Actuate Therapeutics receives FDA Rare Pediatric Disease Designation for elraglusib in Ewing sarcoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Rare Pediatric Disease Designation for elraglusib, a GSK-3β inhibitor, to treat Ewing sarcoma.","Designation makes elraglusib eligible for a Priority Review Voucher (PRV) upon future NDA approval; PRV can be sold.","Ongoing Phase 1/2 trial (NCT04239092) in relapsed/refractory EWS; topline Phase 1 data expected in 2H 2025.","Early data: two ongoing durable Complete Responses in first six patients; 8 patients enrolled to date.","Ewing sarcoma is the second most prevalent malignant tumor in children/adolescents; ~25% present with metastatic disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209137,"accession_number":"0001683168-24-005919","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Actuate Therapeutics replaces auditor after KMJ joins Crowe; prior reports cite going concern and material weakness","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["KMJ Corbin & Company LLP resigned as auditor on Aug 19, 2024; Crowe LLP appointed same day.","KMJ audit reports for FY2023 and FY2022 included a going-concern explanatory paragraph about substantial doubt.","Company reported a material weakness in internal control over financial reporting due to inadequate review of clinical trial expense accruals.","No disagreements between Company and KMJ on accounting principles or auditing scope.","KMJ's professional staff joined Crowe LLP on May 20, 2024; change is related to that merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209136,"accession_number":"0001104659-24-089693","cik":1652935,"company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Actuate Therapeutics completes IPO of 2.8M shares at $8.00, net proceeds $19.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed Aug 14, 2024: 2,800,000 shares at $8.00/share, net proceeds $19.2M.","Underwriters granted 30-day option to purchase up to 420,000 additional shares.","New independent directors appointed: Jason Keyes, Roger Sawhney, Amy Ronneberg; Les Kreis resigned.","Charter amended: authorized common stock increased to 200M shares; classified board created.","Exclusive forum provisions for federal securities law claims adopted in charter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":47133925.900473945,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}